Evidence map›Paper›PMID 38663502›Full record

ArticleAmerican journal of ophthalmology2024

Prevalence, Patterns, and Predictors of SARS-CoV-2 RNA and Culturable Virus in Tears of a Case-Ascertained Household Cohort.

Matthew So, Sarah A Goldberg, Scott Lu, Miguel Garcia-Knight, Michelle C Davidson, Michel Tassetto, Victoria Wong Murray, Khamal Anglin, Jesus Pineda-Ramirez, Jessica Y Chen and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Matthew SoInstitute for Global Health Sciences (M.S, S.A.G, S.L, K.A, J.P.-R, J.Y.C, J.D.K), University of California, San Francisco, California, USA.
Sarah A GoldbergInstitute for Global Health Sciences (M.S, S.A.G, S.L, K.A, J.P.-R, J.Y.C, J.D.K), University of California, San Francisco, California, USA; Department of Epidemiology and Biostatistics (S.A.G, S.L, P.R.R, J.N.M, J.D.K), University of California, San Francisco, San Francisco, California, USA.
Scott LuInstitute for Global Health Sciences (M.S, S.A.G, S.L, K.A, J.P.-R, J.Y.C, J.D.K), University of California, San Francisco, California, USA; Department of Epidemiology and Biostatistics (S.A.G, S.L, P.R.R, J.N.M, J.D.K), University of California, San Francisco, San Francisco, California, USA.
Miguel Garcia-KnightDepartment of Microbiology and Immunology (M.G.-K, M.T), University of California, San Francisco, San Francisco, California, USA.
Michelle C DavidsonSchool of Medicine (M.C.D), University of California, San Francisco, San Francisco, California, USA.
Michel TassettoDepartment of Microbiology and Immunology (M.G.-K, M.T), University of California, San Francisco, San Francisco, California, USA.
Victoria Wong MurraySchool of Medicine (V.W.M), Cooper Medical School of Rowan University, Camden, New Jersey, USA.
Khamal AnglinInstitute for Global Health Sciences (M.S, S.A.G, S.L, K.A, J.P.-R, J.Y.C, J.D.K), University of California, San Francisco, California, USA.
Jesus Pineda-RamirezInstitute for Global Health Sciences (M.S, S.A.G, S.L, K.A, J.P.-R, J.Y.C, J.D.K), University of California, San Francisco, California, USA.
Jessica Y ChenInstitute for Global Health Sciences (M.S, S.A.G, S.L, K.A, J.P.-R, J.Y.C, J.D.K), University of California, San Francisco, California, USA.
Paulina R RugartDepartment of Epidemiology and Biostatistics (S.A.G, S.L, P.R.R, J.N.M, J.D.K), University of California, San Francisco, San Francisco, California, USA.
Eugene T RichardsonDepartment of Global Health and Social Medicine (E.T.R), Harvard Medical School, Boston, Massachusetts, USA; Division of Infectious Diseases (E.T.R), Brigham and Women's Hospital, Boston, Massachusetts, USA.
Melissa Briggs-HagenCoronavirus and Other Respiratory Viruses Division (M.B.H, C.M.M), National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Claire M MidgleyCoronavirus and Other Respiratory Viruses Division (M.B.H, C.M.M), National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Raul AndinoDepartment of Microbiology and Immunology (M.G.-K, M.T), University of California, San Francisco, San Francisco, California, USA.
Gerami D SeitzmanF.I. Proctor Foundation (G.D.S, J.G, J.D.K), University of California, San Francisco, San Francisco, California, USA; Department of Ophthalmology (G.D.S, J.G), University of California, San Francisco, California, USA.
John GonzalesF.I. Proctor Foundation (G.D.S, J.G, J.D.K), University of California, San Francisco, San Francisco, California, USA; Department of Ophthalmology (G.D.S, J.G), University of California, San Francisco, California, USA.
Michael J PelusoDivision of HIV, Infectious Diseases and Global Medicine (M.J.P), Zuckerberg San Francisco General Hospital, San Francisco, California, USA.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics (S.A.G, S.L, P.R.R, J.N.M, J.D.K), University of California, San Francisco, San Francisco, California, USA.
John Daniel KellyInstitute for Global Health Sciences (M.S, S.A.G, S.L, K.A, J.P.-R, J.Y.C, J.D.K), University of California, San Francisco, California, USA; Department of Epidemiology and Biostatistics (S.A.G, S.L, P.R.R, J.N.M, J.D.K), University of California, San Francisco, San Francisco, California, USA; F.I. Proctor Foundation (G.D.S, J.G, J.D.K), University of California, San Francisco, San Francisco, California, USA; Division of Hospital Medicine (J.D.K), San Francisco Veterans Affairs Medical Center, San Francisco, California, USA. Electronic address: Dan.Kelly@ucsf.edu.
University of California, San Francisco · USCenters for Disease Control and Prevention · USBrigham and Women's Hospital · USCooper Medical School of Rowan University · USSan Francisco General Hospital · USSan Francisco VA Medical Center · US

Funding

Sjögren’s Team for Accelerating Medicines Partnership (STAMP)UC2DE032254 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALAN N BAER, A Darise Farris · 2022 to 2026
$8.8M
Parasitic Ulcer Treatment Trial - Diversity SupplementUG1EY033284 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jeremy David Keenan, Gerami D Seitzman · 2023 to 2026
$5.3M
Sjögren's International Collaborative Clinical Alliance Next Generation Studies (SICCA-NextGen)U01DE028891 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHIBOSKI, CAROLINE HELENE · 2020 to 2024
$4.0M
Non-Sjogren's Syndrome-and Sjogren's Syndrome-related Keratoconjunctivitis SICCA: A Spectrum of Inflammatory Dry EyeK23EY026998 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GONZALES, JOHN ALEXANDER · 2016 to 2020
$1.3M
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
Social Epidemiology of Ebola Virus DiseaseK08AI139361 · NIAID · HARVARD MEDICAL SCHOOL · PI RICHARDSON, EUGENE THOMAS · 2019 to 2022
$751k
Understanding the epidemiology and natural history of unrecognized Ebola virus infectionK23AI146268 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KELLY, JOHN DANIEL · 2019 to 2022
$748k
CDC HHS 75D30120C08009NEI NIH HHS K23 EY026998NEI NIH HHS UG1 EY033284NIAID NIH HHS K08 AI139361NIAID NIH HHS K23 AI146268NIAID NIH HHS K23 AI157875NIAID NIH HHS L30 AI147159NIDCR NIH HHS U01 DE028891NIDCR NIH HHS UC2 DE032254
6 · The paper itself

Abstract

purposeTo investigate the prevalence, patterns, and predictors of SARS-CoV-2 RNA and culturable virus in tears of a case-ascertained household cohort.

designProspective, longitudinal case-ascertained household cohort identified through convenience sampling.

methodsThis analysis was restricted to individuals who were non-hospitalized, symptomatic, and tested positive for SARS-CoV-2 by nasal RT-PCR. Tears and anterior nasal biospecimens were serially collected throughout the acute period. Tears specimens were collected by the study staff using Schirmer test strips, and nasal specimens were self-collected. For both, SARS-CoV-2 RNA was quantified using qRT-PCR, and culturable virus was detected using presence of cytopathic effect (CPE) in tissue culture; positive CPE was confirmed by a qRT-PCR step. A series of cross-sectional unadjusted analyses were performed investigating the relationship between different sociodemographic determinants and biological factors associated with tears RNA positivity.

resultsAmong the 83 SARS-CoV-2 infected participants, 10 (12%) had at least one RNA-positive tears specimen. Amongst these 10, 5 (50%) had concurrent presence of culturable virus, at a median of 7 days postsymptom onset (IQR: 4-7 days) (absolute range: 4-8 days).

conclusionsIn this longitudinal cohort, we found evidence of culturable virus in the tears of a small proportion of nonhospitalized SARS-CoV-2 infected individuals. Current public health infection precautions do not account for transmission via tears, so these findings may improve our understanding of potential sources of SARS-CoV-2 transmission and contribute to developing future guidelines.

Indexed as

COVID-19RNA, ViralSARS-CoV-2TearsAdultAgedCOVID-19 Nucleic Acid TestingCross-Sectional StudiesEye Infections, ViralFamily CharacteristicsFemaleHumansLongitudinal StudiesMaleMiddle AgedPrevalenceRNA, Viral

Identifiers

PMID38663502
PMCPMC11645976
OpenAlexW4395053735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.